Humanetics Corporation
Records under this name other than the patents Humanetics Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 19 patents it holds.
Back to Humanetics Corporation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,623,004 | Administration of a Therapeutic Amount of Genistein to Mitigate Erectile Dysfunction Resulting from Radiation Therapy for Prostate Cancer Only Throughout a Defined Administration Period Commencing Shortly Before and Concluding After Radiation Therapy Formerly held In force · High confidence | In force | High confidence | |
| US 11,779,644 | Sensitizing cells to proton radiation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,129,894 | Sensitizing Cells to Proton Radiation Formerly held In force · High confidence | In force | High confidence | |
| US 7,199,116 | Method of Modulating the Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the Dieting Mammal Formerly held Term ended Term ended Sep 26, 2024 · High confidence | Term ended | Term ended Sep 26, 2024 | High confidence |
| US 7,109,358 | Process for the Preparation of Isoflavones Term ended Term ended Apr 23, 2023 · High confidence | Term ended | Term ended Apr 23, 2023 | High confidence |
| US 7,553,829 | Treatment of Chronic Fatigue Syndrome and Fibromyalgia Syndrome Formerly held Lapsed on the fee record Ended Jun 30, 2021 · High confidence | Lapsed on the fee record | Ended Jun 30, 2021 | High confidence |
| US 6,518,318 | Stimulating transport of glucose into animal tissue by the administration of pinitol Term ended Term ended May 30, 2021 · From the USPTO record | Term ended | Term ended May 30, 2021 | From the USPTO record |
| US 6,153,606 | Memory enhancement by the administration of .DELTA.5-androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof Formerly held Term ended Term ended Oct 16, 2018 · From the USPTO record | Term ended | Term ended Oct 16, 2018 | From the USPTO record |
| US 6,489,313 | Memory by the administration of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and 3&bgr; esters Formerly held Term ended Term ended Oct 16, 2018 · From the USPTO record | Term ended | Term ended Oct 16, 2018 | From the USPTO record |
| US 6,593,316 | Use of DELTA5-ANDROSTENE-3BETA OL-7,17-Dione in the Treatment of Lupus Erythematosus Formerly held Lapsed on the fee record Ended Jul 15, 2011 · Low confidence | Lapsed on the fee record | Ended Jul 15, 2011 | Low confidence |